Beroni Group Limited Acquires Majority Interest in Anti-Cancer Drug Development Company

Sydney, Australia – Beroni Group an Australia-based diversified biopharmaceutical enterprise today announces that it has completed its majority acquisition of the Sydney-based anticancer drug development company, PENAO Pty Ltd. As a result of this acquisition, Beroni now owns 60% of PENAO Pty Ltd’s shares. PENAO Pty Ltd was incorporated in 2019 and enjoys the support of the University of New South Wales, Sydney, …

Sydney, Australia (ABN Newswire) – Beroni Group (OTCMKTS:BNIGF) (NSX:BTG), an Australia-based diversified biopharmaceutical enterprise today announces that it has completed its majority acquisition of the Sydney-based anticancer drug development company, PENAO Pty Ltd. As a result of this acquisition, Beroni now owns 60% of PENAO Pty Ltd’s shares.

PENAO Pty Ltd was incorporated in 2019 and enjoys the support of the University of New South Wales, Sydney, Australia who becomes a 40% shareholder while Beroni retains the call option to increase its 60% shareholding. It has a highly experienced Board of Directors and Management, including its Chair Dr Peter French who has held directorships in several successful biotechnology companies.

PENAO Pty Ltd is focused on the research, development and commercialization of the potential anti-cancer small molecule drug, PENAO. This next generation adenine nucleotide translocase (ANT) inhibitor was shown to be safe and well-tolerated in a 26-patient clinical trial conducted in Australia where encouraging efficacy data was observed.

PENAO has been shown to accumulate in cells at a rate 85-fold faster than its predecessor gold standard GSAO, which results in a 44-fold increased anti-proliferative activity and a ~20-fold increase in anti-tumour efficacy in non-clinical studies. Its faster intracellular accumulation rate and slower extrusion rate could circumvent multidrug resistance, making it potentially a greatly improved anti-cancer agent. A larger Phase I/II clinical trial will be conducted in China and Australia to demonstrate PENAO’s efficacy in patients with advanced solid tumours as a stand-alone therapy and in combination with the established treatment rapamycin. Peer-reviewed publications on study results can be viewed on Beroni’s website: https://www.beronigroup.com/anti-cancer-drugs/.

“I am delighted to partner with Beroni and advise on PENAO’s development as a very promising treatment for cancer patients who have not responded to standard therapy,” commented Professor Phillip Hogg, co-creator of the drug.

“There is a significant and growing unmet medical need for novel, effective anti-cancer drugs. The number of new cancer cases worldwide in 2020 is estimated to have risen to 19.3 million and to reach 28.4 million in 2040. It is our aspiration that PENAO will become a new breakthrough therapy for treating cancer. We will make the most use of our multicentered clinical network to accelerate the development and commercialization of PENAO,” commented Jacky Zhang, Chair and CEO of Beroni.

About Beroni Group Limited:

Beroni Group (NSX:BTG) (OTCMKTS:BNIGF) is an international biopharmaceutical enterprise dedicated to the innovation and commercialization of drugs and therapies to combat various global diseases such as cancer and infectious diseases. Its diversified portfolio is comprised of a US FDA approved virus diagnostic kit, an e-commerce platform for the sale of pharmaceutical products and a development pipeline targeting oncology and cell therapies. Beroni has operations in Australia, United States, China and Japan. To learn more about Beroni, please visit www.beronigroup.com.

Source:
Beroni Group Limited

Contact:
Dragon Gate Investment Partners LLC
Tel: +1(646)-801-2803
Email: BNIGF@dgipl.com

News Provided by ABN Newswire via QuoteMedia

Resolution Minerals Ltd Drilling Program at Sunrise Gold Prospect Completed

Adelaide, Australia (ABN Newswire) – Resolution Minerals Ltd (ASX:RML) (FRA:NC3) is pleased to announce that it has completed the Company’s first drilling program on the Sunrise Gold Prospect at the 64North Project in Alaska. Drilling was conducted along an existing access road, targeting outcropping granite hosted mineralisation, analogous in style to Kinross’s Fort Knox Gold Mine, which is one of Alaska’s most profitable mines. The Sunrise Prospect was identified in 2020 by a RML trenching program and is located less than 5km from Northern Star’s operating Pogo Gold Mine.

Summary

– A 1400m long “fence line” of 27 shallow RAB drill holes designed to test outcropping mineralisation at the Sunrise Prospect has been completed.

Keep reading... Show less

Argyle Diamond Mine Closure: The End of a Sparkling Era

Pink and red diamonds are among the most special gems in the world. The value of these highly sought-after natural stones speaks for itself, but their rarity has arguably increased since the closure of Rio Tinto’s (ASX:RIO,LSE:RIO,NYSE:RIO) Argyle mine.

The asset, which ceased mining activity on November 3, 2020, had been in operation since 1983. In that time, 865 million carats of rough diamonds were produced.

The unique geological chemistry of the Western Australia location birthed the rarest hues, including champagne, cognac, blue, violet and of course, the coveted Argyle pink and red diamonds. Millions of carats of white diamonds were produced at the prolific property as well.

Keep reading... Show less

Argyle Diamond Mine Closure: The End of a Sparkling Era

Pink and red diamonds are among the most special gems on earth. The value of these highly sought-after natural stones speaks for itself, but their rarity has arguably increased since the closure of Rio Tinto’s (ASX:RIO,LSE:RIO,NYSE:RIO) Argyle mine.

The asset, which ceased mining activity on November 3, 2020, had been in operation since 1983. In that time, 865 million carats of rough diamonds were produced.

The unique geological chemistry of the Western Australia location birthed the rarest hues, including champagne, cognac, blue, violet and of course, the coveted Argyle pink and red diamonds. Millions of carats of white diamonds were produced at the prolific property as well.

Keep reading... Show less

Graphite Metallurgical Test Work Update

Highlights:

  • Bulk sample of Springdale graphite concentrate estimated to be completed in Q2 2021.
  • Concentrate material will then be sent to Germany to test its amenability for the production of battery anode material suitable for use in EVs.
  • Final test results expected in Q3 2021.

Comet Resources Ltd (ASX:CRL) is pleased provide an update on ongoing test work on natural flake graphite from its Springdale Graphite Project (Springdale) located in Western Australia. Both excellent grade and recoveries were achieved on initial tests, leading to commencement of work to produce a bulk sample for further testing. Importantly, the graphite concentrates previously produced demonstrated a unique and potentially very valuable characteristic in its small size distribution, with two-thirds of the product passing the 38 µm size fraction screen. Generally, this small size fraction of graphite is a by-product of processing of larger flake fractions, which produces smaller size graphite, but in doing so also damages the smaller flake material in the process, reducing their performance and value. Deposits that contain high quality ultra-fine graphite are uncommon and are potentially suitable for supplying the expanding battery anode market, which continues to grow as the sales of electric vehicles (EVs) increase. Graphite suitable for battery anode production also achieves premium pricing in graphite markets, making it a highly sought-after product.

Keep reading... Show less

Medallion Completes Diagnostic Testing with Australian Nuclear Science and Technology Organization

Medallion Resources Ltd. (TSX-V: MDL; OTCQB: MLLOF; Frankfurt: MRDN) “Medallion” or the “Company”) announces completion of a suite of diagnostic test work at the Australian Nuclear Science and Technology Organization (ANSTO) in Sydney, to extract rare earth elements (REE) from mineral sand monazite. The monazite was sourced from an Australian mineral sand mine. Discussion is ongoing with additional prospective suppliers.

Mineral sand monazite is an abundant REE-rich feedstock, that can be accessed as a by-product from global mineral-sand mines that target zirconium and titanium, without the need for additional mining. Medallion’s business model is centered on the Medallion Monazite Process , a transferable and scalable technology designed to accept multiple mineral-sand monazite feedstocks and extract high-value REEs with high efficiency, high recovery and zero liquid waste.

Keep reading... Show less

Top News

Related News